MapLight Therapeutics, Inc.

MPLT Nasdaq SEC CIK 1770069
Follow MapLight Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$51.6M −75.5% vs same quarter last year
EPS, diluted −$0.97 +97.4% vs same quarter last year
Operating cash flow −$35.7M −12.2% vs same quarter last year
Operating income −$55.3M −75.7% vs same quarter last year
Net income by quarter
−$21.2M
−$22.3M
−$29.8M
−$29.4M
−$79.5M
−$60.7M
−$60.2M
−$51.6M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing